GlaxoSmithKline (GSK) Receives Hold Rating from Deutsche Bank

GlaxoSmithKline (LON:GSK)‘s stock had its “hold” rating reissued by Deutsche Bank in a report issued on Tuesday. They currently have a GBX 1,525 ($19.93) target price on the stock. Deutsche Bank’s target price would indicate a potential upside of 0.74% from the stock’s current price.

Several other equities research analysts have also commented on the stock. Credit Suisse Group set a GBX 1,600 ($20.91) price objective on shares of GlaxoSmithKline and gave the stock a “neutral” rating in a research note on Tuesday. Cfra set a GBX 1,620 ($21.17) price objective on shares of GlaxoSmithKline and gave the stock a “neutral” rating in a research note on Tuesday. Goldman Sachs Group set a GBX 1,900 ($24.83) price objective on shares of GlaxoSmithKline and gave the stock a “buy” rating in a research note on Monday. HSBC dropped their price objective on shares of GlaxoSmithKline from GBX 2,030 ($26.53) to GBX 2,000 ($26.13) and set a “buy” rating on the stock in a research note on Wednesday, November 28th. Finally, JPMorgan Chase & Co. reissued a “neutral” rating and set a GBX 1,600 ($20.91) price objective on shares of GlaxoSmithKline in a research note on Friday, November 23rd. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating and eight have issued a buy rating to the stock. GlaxoSmithKline presently has an average rating of “Hold” and a consensus target price of GBX 1,518.84 ($19.85).

LON:GSK traded up GBX 15.80 ($0.21) during mid-day trading on Tuesday, hitting GBX 1,513.80 ($19.78). 14,516,800 shares of the company’s stock were exchanged, compared to its average volume of 9,120,000. GlaxoSmithKline has a one year low of GBX 1,235.20 ($16.14) and a one year high of GBX 1,724.50 ($22.53).

About GlaxoSmithKline

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Further Reading: What is an SEC Filing?

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit